Stanley E. Gilliland III, PhD is Senior Vice President of Chemistry and Material Science at Sapphire Sciences, a scientific consulting firm that provides strategic scientific and regulatory support to companies developing next-generation nicotine products. His work spans regulatory strategy and scientific advisory services, helping companies navigate complex regulatory pathways from early product development through all phases of the regulated product lifecycle.
Dr. Gilliland works with multidisciplinary teams to provide expert guidance on regulatory strategy and the design of scientific testing programs aligned with FDA expectations. His expertise reflects a comprehensive understanding of how FDA evaluates the totality of evidence, including manufacturing, product characterization, nonclinical testing, and clinical and behavioral studies in the context of determining whether tobacco and nicotine products meet the agency’s APPH standard.
With experience supporting both emerging and established companies, Dr. Gilliland focuses on translating complex science into clear regulatory narratives. His work increasingly explores how emerging tools, including artificial intelligence and advanced analytics, can enhance product research, regulatory science, and evidence generation within regulated industries.